The FDA last week fast-tracked its approval of...

...Clovis Oncology's Rubraca for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in patients who have not responded to previous treatments. The PARP inhibitor, which was approved as a maintenance therapy for ovarian cancer patients in 2018, will face off against AstraZeneca and Merck's Lynparza and GlaxoSmithKline's Zejula in the prostate cancer market. For the treatment of ovarian cancer, Rubraca holds preferred status under the pharmacy benefit for 4% of all covered lives, growing to 35% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 5/18/20